ELGAN Pharma
Rinat Aizen-Benbenishti is a seasoned professional in pharmacovigilance, currently serving as the Head of Pharmacovigilance at ELGAN Pharma since June 2025. Prior to this role, Rinat led the pharmacovigilance department at BioLineRx from April 2023 to June 2025. Rinat's extensive experience at Teva Pharmaceuticals spans over two decades, encompassing various leadership positions such as Pharmacovigilance Director in multiple capacities and Pharmacovigilance Associate Director. Rinat holds a Bachelor of Pharmacy from The Hebrew University of Jerusalem and both a Master of Science in Microbiology and a Bachelor of Science in Biology from Tel Aviv University.
This person is not in any teams
This person is not in any offices
ELGAN Pharma
We named our company ELGAN Pharma, as we are dedicated to improving outcome for babies who are Extremely Low Gestational Age Newborns (ELGANs). This means they are born more than 3 months before term. Premature birth is the number one cause of newborn deaths. With improved standard-of-care worldwide, survival rate increases, leading to the need of improving outcome and quality of life. ELGAN Pharma is a neonatology-focused biotechnology company, dedicated to developing safe tailored therapies to address medical problems and developmental difficulties that are common in babies born very early.